| 000 | 01753 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250516085951.0 | ||
| 264 | 0 | _c20120906 | |
| 008 | 201209s 0 0 eng d | ||
| 022 | _a1744-7674 | ||
| 024 | 7 |
_a10.1517/13543776.2012.682572 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFerreira, Anderson J | |
| 245 | 0 | 0 |
_aTherapeutic targeting of the angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas cascade in the renin-angiotensin system: a patent review. _h[electronic resource] |
| 260 |
_bExpert opinion on therapeutic patents _cMay 2012 |
||
| 300 |
_a567-74 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAngiotensin I _xchemistry |
| 650 | 0 | 4 |
_aAngiotensin II _xmetabolism |
| 650 | 0 | 4 | _aAngiotensin-Converting Enzyme 2 |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCardiovascular Agents _xchemistry |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aEnzyme Activation |
| 650 | 0 | 4 |
_aEnzyme Activators _xchemistry |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLegislation, Drug |
| 650 | 0 | 4 | _aMolecular Structure |
| 650 | 0 | 4 | _aPatents as Topic |
| 650 | 0 | 4 |
_aPeptide Fragments _xchemistry |
| 650 | 0 | 4 |
_aPeptidyl-Dipeptidase A _xmetabolism |
| 650 | 0 | 4 | _aProto-Oncogene Mas |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins _xagonists |
| 650 | 0 | 4 |
_aReceptors, G-Protein-Coupled _xagonists |
| 650 | 0 | 4 |
_aRenin-Angiotensin System _xdrug effects |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 700 | 1 | _aBader, Michael | |
| 700 | 1 | _aSantos, Robson A S | |
| 773 | 0 |
_tExpert opinion on therapeutic patents _gvol. 22 _gno. 5 _gp. 567-74 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/13543776.2012.682572 _zAvailable from publisher's website |
| 999 |
_c21709640 _d21709640 |
||